June 18, 2018 / 6:09 AM / 4 months ago

BRIEF-Karolinska Development: Aprea Therapeutics presents positive results from study with APR-246

June 18(Reuters) - Karolinska Development:

* SAID ON SUNDAY APREA THERAPEUTICS PRESENTS CONTINUED POSITIVE DEVELOPMENT FOR THE CANDIDATE DRUG APR-246 IN PATIENTS WITH TP53 MUTANT MYELODYSPLASTIC SYNDROMES AT THE 2018 EUROPEAN HEMATOLOGY ASSOCIATION ANNUAL MEETING IN STOCKHOLM

* THE RESULTS FROM THE PHASE IB/II COMBINATION STUDY WITH APR-246 AND AZACITIDINE SHOW AN OVERALL RESPONSE RATE (ORR) OF 100 PER CENT IN 9 EVALUABLE PATIENTS

Source text for Eikon:

Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below